ORGN 86 |
| Co-crystals are emerging as interesting and underexploited compositions in the pharmaceutical industry. Co-crystals of drug products have been prepared by several techniques, including crystallization from solution and mechanical grinding. The co-crystals often display different physical properties from the active pharmaceutical ingredient (API) such as modified dissolution, enhanced bioavailability and altered physical stability. The co-crystal of carbamazepine and saccharin was found to be less hygroscopic than the parent drug and showed an improved dissolution profile compared to the marketed product (Tegretol®). The co-crystal of celecoxib (active drug in Celebrex®) and nicotinamide exhibits increased kinetic solubility relative to the API and improved stability relative to the sodium salt of celecoxib. This presentation will demonstrate how a molecular self-assembly approach can be used to prepare co-crystals with the aim of identifying new pharmaceutical materials, which can modify physical properties and performance. |
|
Molecular Recognition and Self-Assembly
1:00 PM-4:20 PM, Sunday, August 19, 2007 BCEC -- 258A, Oral
Division of Organic Chemistry |